Antifungal susceptibility testing in 62 French hospitals;Pratique de l'antifongigramme dans 62 hôpitaux français

Journal de Mycologie Medicale

Volumn 15, Issue 4, 2005, Pages 197-210

  Blanc, V ^a   Eloy, O ^b   Sanchez, R ^c   Mallie M ^d  

^a Centre Hospitalier d'Antibes   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

^c Physico et Toxico Chimie de i' Environment   (France)

^d UNIV MONTPELLIER   (France)

Author keywords

Antifungal susceptibility testing; Candida; France; Hospitals; Multicentric survey

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BLOOD CULTURE; CANDIDA; CONTROLLED STUDY; FRANCE; FUNGAL STRAIN; FUNGUS ISOLATION; HOSPITAL; LABORATORY TEST; MYCOLOGY; NONHUMAN; PHYSICIAN; QUALITY CONTROL; QUESTIONNAIRE; YEAST;

BACTERIA (MICROORGANISMS); CANDIDA; FUNGI;

EID: 28844478932     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mycmed.2005.09.001     Document Type: Article

References (42)

1. S. Arikan, and J.H. Rex New agents for treatment of systemic fungal infections Emerg. Drugs 5 2000 135 160
2. A.L. Barry, M.A. Pfaller, S.D. Brown, A. Espinel-Ingroff, M.A. Ghannoum, and C. Knapp Quality control limits for broth microdilution susceptibility tests of ten antifungal agents J. Clin. Microbiol. 38 2000 3457 3459
3. J. Bille Structures, modes d'actions et ḿcanismes de ŕsistance des antifongiques syst́miques Conf́rence de consensus commune SFAR, SPILF 2004 SRLF, Elsevier Ed Paris 32 38
4. S. Bretagne Diagnostic au laboratoire des candidoses et aspergilloses invasives Conf́rence de consensus commune SFAR, SPILF 2004 SRLF, Elsevier Ed Paris 14 22
5. ® with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species J. Clin. Microbiol. 40 2002 3841 3844
6. Comité de l'antibiogramme de la Société française de microbiologie (CA-SFM). Communiqué 2004. http://www.sfm.asso.fr.
7. Conf́rence de consensus commune SFAR SPILF, SRLF. Prise en charge des aspergilloses et candidoses invasives de l'adulte. Texte long Conf́rence de consensus commune SFAR, SPILF 2004 SRLF, Elsevier Ed Paris 5 13
8. M. Cuenca-Estrella, W. Lee-Yang, M.A. Ciblak, B.A. Arthington-Skaggsd, E. Mellado, and D.W. Warnock Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species Antimicrob. Agents Chemother. 46 2002 3644 3647
9. E. Dannaoui Int́r̂t des tests de sensibilit́ in vitro dans la prise en charge des candidoses et aspergilloses invasives conf́rence de consensus commune SFAR, SPILF 2004 SRLF, Elsevier Ed Paris 52 59
10. E.J. Dasbach, G.M. Davies, and S.M. Teutsch Burden of aspergillosis-related hospitalizations in the united states Clin. Infect. Dis. 31 2000 1524 1528
11. E. Drouhet, T. Barale, J. Bastide, M. Mallí, M.F. Biava, and L. Kures Standardisation de l'antibiogramme antifongique. Rapport du groupe d'́tudes de la Socít́ fraņaise de mycologie ḿdicale Bull. Soc. Myc. Med. 10 1981 131 134
12. A. Druetta, A. Freydìre, R. Guinet, and Y. Gille Evaluation of five commercial antifungal susceptibility testing systems Eur. J. Clin. Microbiol. Infect. Dis. 12 1993 336 342
13. P. Eggiman, J. Garbino, and D. Pittet Epidemiology of Candida species infections in critically ill non immunosuppressed patients Lancet Infect. Dis. 3 2003 685 702
14. ® procedure for testing susceptibilities of Aspergillus sp. to caspofungin (MK-0991) J. Clin. Microbiol. 41 2003 403 409
15. European Committee on Antimicrobial Susceptibility testing EUCAST discussion document E.Dis 7.1 June 2002. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts Clin. Microbiol. Infect. 9 2003 1 8
16. M.R. Jacobs How can we predict bacterial eradication? Int. J. Infect. Dis. 7 suppl.1 2003 S13 S20
17. B.J. Kullberg, and A.M. Oude Lashof Epidemiology of opportunistic invasive mycoses Eur. J. Med. Res. 7 2002 183 191
18. P. Leophonte, M. Mularczyk, and P. Geslin Pneumonia caused by resistant pneumococci Presse Med. 22 1993 914 918
19. V. Lorian, and L. Burns Predictive value of susceptibility tests for the outcome of antibacterial therapy J. Antimicrob. Chemother. 25 1990 175 181
20. O. Marchetti, J. Bille, U. Fluckiger, P. Eggiman, C. Ruef, and J. Garbino Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000 Clin. Infect. Dis. 38 2004 311 320
21. National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard M38-P. National Committee for Clinical Laboratory Standards, Wayne, Pa 1998.
22. National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of yeast, 2nd ed. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa 2002.
23. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing; eleventh informational supplement, vol.22, no 1. M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa 2002.
24. L. Ostrosky-Zeichner, J.H. Rex, P.G. Pappas, R.J. Hamill, R.A. Larsen, and H.W. Horowitz Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States Antimicrob. Agents Chemother. 47 2003 3149 3154
25. P.G. Pappas, J.H. Rex, J.D. Sobel, S.G. Filler, W.E. Dismukes, and T.J. Walsh Guidelines for treatment of candidiasis Clin. Infect. Dis. 38 2004 161 189
26. M.G. Petri, J. Konig, H.P. Moecke, H.J. Gramm, H. Barkow, and P. Kujath Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich society for chemotherapy, divisions of mycology and pneumonia research Intensive Care Med. 23 1997 317 325
27. ® J. Clin. Microbiol. 39 2001 339 342
28. M. Pfaller, and R. Wenzel Impact of the changing epidemiology of fungal infection since the 1990s Eur. J. Clin. Microbiol. Infect. Dis. 11 1992 287 291
29. ® and reference microdilution method for determining voriconazole and itraconazole MICs J. Clin. Microbiol. 41 2003 1126 1129
30. ® methods: report from the ARTEMIS global antifungal susceptibility program, 2001 J. Clin. Microbiol. 41 2003 1440 1446
31. M.A. Pfaller, D.J. Diekema International fungal surveillance participant group Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida Clin. Microbiol. Infect. 10 Suppl.1 2004 11 23
32. M. Plempel, D. Berg, K.H. Büchel, and D. Abbink Test methods for antifungal agents - a critical review Mykosen 30 1987 28 37
33. S.W. Redding, M.A. Pfaller, and S.A. Messer Variations in fluconazole susceptibility and DNA subtyping of multiple C.:albicans colonies from patients with AIDS and oral candidiasis suffering from one or more episodes of infection J. Clin. Microbiol. 35 1997 1761 1765
34. J.H. Rex, M.A. Pfaller, J.N. Galgiani, M.S. Bartlett, A. Espinel-Ingroff, M.A. Ghannoum Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infection Clin. Infect. Dis. 24 1997 235 247
35. J.H. Rex, M.A. Pfaller, T. Walsh, V. Chaturvedi, A. Espinel-Ingroff, and M.A. Ghannoum Antifungal susceptibility testing: practical aspects and current challenges Clin. Microbiol. Rev. 14 2001 643 648
36. J.H. Rex, and M.A. Pfaller Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35 2002 982 989
37. H. Richet, P. Roux, C. Des Champs, Y. Esnault, A. Andremont French Candidemia Study Group. Candidemia in French hospitals: incidence rates and characteristics Clin. Microbiol. Infect. 8 2002 405 412
38. C.J. Soussy Le CA-SFM et la normalisation de l'antibiogramme en Europe Bull. Soc. Fr. Microbiol. 19 2004 191 193
39. A.M. Tortorano, J. Peman, H. Bernhardt, L. Klingspor, C.C. Kibbler, and O. Faure Epidemiology of candidaemia in Europe: results of 28-month european confederation of medical mycology (ECMM) hospital-based surveillance study Eur. J. Clin. Microbiol. Infect. Dis. 23 2004 317 322
40. O. Vermorel, B. Lebeau, F. Claustre, and R. Grillot Antifongigramme:: interpŕtation et choix d'une technique Ann. Biol. Clin. (Paris) 47 1989 85 90
41. ® and national committee for clinical laboratory standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates Antimicrob. Agents Chemother. 39 1995 2520 2522
42. V.L. Yu, C.C.C. Chiou, C. Feldman, A. Ortqvist, J. Rello, and A.J. Morris An international prospective study of pneumococcal bacteriema: correlation with in vitro resistance, antibiotics administered, and clinical outcome Clin. Infect. Dis. 37 2003 230 237